

## **USE OF IMMUNOSUPPRESSIVE AGENTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) AND DIABETIC RETINOPATHY**

### **SUMMARY**

The National Eye Institute, Laboratory of Immunology is seeking statements of capability or interest from parties interested in licensing or co-development research to further develop, evaluate, or commercialize immunosuppressive agents for the treatment of age related macular degeneration

### **REFERENCE NUMBER**

E-198-2008

### **PRODUCT TYPE**

- Therapeutics

### **KEYWORDS**

- Therapeutics
- macular degeneration
- retinopathy
- immunotherapeutics

### **COLLABORATION OPPORTUNITY**

This invention is available for licensing and co-development.

### **CONTACT**

Alan Hubbs

NEI - The National Eye Institute

240-276-5532

[Alan.Hubbs@nih.gov](mailto:Alan.Hubbs@nih.gov)

### **DESCRIPTION OF TECHNOLOGY**

The National Eye Institute, Laboratory of Immunology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize immunosuppressive agents for the treatment of age related macular degeneration.

AMD belongs to a group of disorders in which the immune system may play an important role. This invention discloses that patients with AMD gain additional therapeutic benefit from combination treatment of immunosuppressive agents and standard-of-care in comparison to standard-of-care alone. This invention slows the progression of choroidal neovascularization (CNV) and may have implications for related pathologies, including diabetic retinopathy. Clinical data from a small, randomized pilot

clinical trial are available.

Development Status: In clinical trials

Patent Status: U.S. Provisional Application No. 61/254,439 filed 23 Oct 2009

#### **POTENTIAL COMMERCIAL APPLICATIONS**

- A method of treatment for AMD.
- A method of treatment for diabetic retinopathy.
- A method of treatment for diseases associated with CNV.

#### **COMPETITIVE ADVANTAGES**

- Likely to be synergistic with existing therapeutics.
- May enable repurposing of some exiting immunosuppressive agents.

#### **DEVELOPMENT STAGE**

- Basic (Target Identification)

#### **PATENT STATUS**

- **Not Patented:** Research Tool--This invention will not be patented.

#### **THERAPEUTIC AREA**

- Cancer/Neoplasm